WORCESTER, Mass., Oct. 20, 2009 (GLOBE NEWSWIRE) -- Pursuant to Nasdaq Marketplace Rule 5250(b)(2), Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced that its consolidated financial statements for the fiscal year ended July 31, 2009 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on October 14, 2009 contained a going concern qualification from its independent registered public accounting firm. Nasdaq Marketplace Rule 5250(b)(2) requires separate public disclosure of a previously issued audit opinion that contains a going concern qualification. This announcement does not represent any change or amendment to the Company’s financial statements for the fiscal year ended July 31, 2009 or to its Annual Report on Form 10-K.
